Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 in Moderate-to-Severe Atopic Dermatitis
CTR20222170Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing CM326 with Placebo (2 arms). Primary endpoint: Percent change in Eczema Area and Severity Index (EASI) from baseline at Week 16. Started Aug 2022; status: completed.
02
Drugs
CM326
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20222170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222170.